Oracle Buys goBalto: Clinical Trial Study Start-Up Meets DX

Oracle Buys goBalto: Clinical Trial Study Start-Up Meets DX

This IDC Perspective provides analyst insights on Oracle's acquisition of goBalto. The document highlights the industry's continuing embrace of digital transformation as it seeks to achieve operational excellence and peak operational efficiencies. The integration of a leading clinical trial study start-up solution with Oracle's top-tier eclinical platform promises to further optimize and streamline the conduct of clinical trials while expanding opportunities for emerging and midtier biopharmaceutical companies to benefit from the unified solution."The ability to automate historically manual clinical trial start-up; digitally capture site data, information, and knowledge; and seamlessly proceed into clinical trial execution within a single eclinical platform is an important advance that should further accelerate and optimize bringing new drugs to market. Life sciences companies, regardless of size, can increasingly leverage leading digitally integrated eclinical platforms and comprehensive clinical trial services to more systematically advance their new drug prospects both efficiently and in a cost-effective manner," said Alan S. Louie, research director, IDC Health Insights Life Science R&D Strategies and Technology.

Please Note: Extended description available upon request.

Executive Snapshot
Situation Overview
Digital Transformation and goBalto
Advice for the Technology Buyer
Learn More
Related Research

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings